The firm’s COVID-19 team is led by Dylan Braverman and Megan Lawless. Dylan spearheads the efforts of this industry’s premier COVID litigation team with Megan, the head of the firm’s Appellate Department, leading the way with our groundbreaking COVID-19 motion and appellate efforts including seminal cases in the United States Court of Appeals for the Second Circuit as well many of the most often cited state court decisions. The team has expanded to approximately 20 partners and associate attorneys.  This extremely close and hardworking team innovates daily, since many of the issues concerning this emerging and complex area of litigation are novel and untested before the appellate courts in New York and nationwide.  The COVID-19 team is recognized as a national leader and has been chosen as lead/co-lead counsel by national insurance carriers and healthcare systems. The team guides a coordinated national response to COVID-19 claims and has the benefit of the institutional knowledge from defending hundreds of complex COVID-19 related claims. No legal team in the nation has more knowledge of the response to COVID-19 by the various health systems and nursing homes in New York and nationally, and no legal team has invested as much time and effort to master the medicine and daily COVID-19 guidance issued by the CDC, WHO, Department of Health, state Governments and other authorities.

The COVID-19 team has a proven track record of success, having obtained dismissal of many COVID-19 claims brought against hospitals, nursing homes and physicians. The COVID-19 team has similarly been the unquestionable leading force towards reversing coordination of COVID-19 claims.

The COVID-19 legal team comprises our most experienced trial attorneys (well over 450 verdicts among team members alone), appellate specialists (who regularly argue before the Appellate Division and the Second Circuit) and transactional/regulatory attorneys.  We have demonstrable expertise in national COVID-19 immunities (e.g., PREP Act), in New York State immunities (e.g., EDTPA) and the Executive Orders covering COVID-19.